Abstract：
BACKGROUND: Lusutrombopag is a thrombopoietin receptor agonist which reduces the need for platelet transfusions before planned invasive procedures. A post hoc analysis of data from the registration trials observed that lusutrombopag-treated patients who achieved a platelet count > 50 × 109/L (responder patients) did so in a median of 6 days and the effect on platelet count lasted for nearly 3 weeks in total. Since patients with cirrhosis often require repeat invasive procedures, this kind of response-time trend sheds light on the possibility of placing more than one invasive procedure within a single course of lusutrombopag treatment.
METHODS: Platelet transfusion represents the gold standard in this setting, but is limited by the risk of adverse events and limited availability.
METHODS: We describe our experience with lusutrombopag in three patients with severe cirrhosis-associated thrombocytopenia who underwent multiple invasive procedures after a single course of treatment.
METHODS: The treatment schedule is lusutrombopag orally 3 mg/daily for 7 days and then a time window of 6 days (day 9-14) for the elective invasive procedure.
RESULTS: All three patients achieved good response to lusutrombopag treatment and were able to undergone more invasive procedures in the same course of treatment without need of platelet transfusion.
CONCLUSIONS: our preliminary experience supports the safety and the effectiveness of lusutrombopag in patients with severe cirrhosis-associated thrombocytopenia who underwent multiple invasive elective procedures after a single course.
METHODS: Platelet transfusion represents the gold standard in this setting, but is limited by the risk of adverse events and limited availability.
METHODS: We describe our experience with lusutrombopag in three patients with severe cirrhosis-associated thrombocytopenia who underwent multiple invasive procedures after a single course of treatment.
METHODS: The treatment schedule is lusutrombopag orally 3 mg/daily for 7 days and then a time window of 6 days (day 9-14) for the elective invasive procedure.
RESULTS: All three patients achieved good response to lusutrombopag treatment and were able to undergone more invasive procedures in the same course of treatment without need of platelet transfusion.
CONCLUSIONS: our preliminary experience supports the safety and the effectiveness of lusutrombopag in patients with severe cirrhosis-associated thrombocytopenia who underwent multiple invasive elective procedures after a single course.
摘要：
背景：Lusutrombopag是一种血小板生成素受体激动剂，可减少计划侵入性手术前的血小板输注需求。对注册试验数据的事后分析发现，lusutrombopag治疗的患者血小板计数>50×109/L（应答患者）的中位数为6天，对血小板计数的影响持续了近3周。由于肝硬化患者通常需要重复侵入性手术，这种响应时间趋势揭示了在lusutrombopag治疗的单个疗程中进行多个侵入性手术的可能性。
方法：血小板输注是这种情况下的黄金标准，但受到不良事件风险和可用性有限的限制。
方法：我们描述了我们在3例严重肝硬化相关血小板减少症患者中使用lusutrombopag的经验，这些患者在单疗程后接受了多次侵入性手术。
方法:治疗方案是lusutrombopag口服3mg/天,持续7天,然后6天的时间窗(第9-14天)用于选择性侵入性手术。
结果：所有3例患者对lusutrombopag治疗均取得了良好的反应，并且能够在相同的治疗过程中进行更多的侵入性手术，而无需输注血小板。
结论：我们的初步经验支持lusutrombopag在重度肝硬化相关性血小板减少症患者中的安全性和有效性，这些患者在单疗程后接受了多个侵入性选择性手术。
方法：血小板输注是这种情况下的黄金标准，但受到不良事件风险和可用性有限的限制。
方法：我们描述了我们在3例严重肝硬化相关血小板减少症患者中使用lusutrombopag的经验，这些患者在单疗程后接受了多次侵入性手术。
方法:治疗方案是lusutrombopag口服3mg/天,持续7天,然后6天的时间窗(第9-14天)用于选择性侵入性手术。
结果：所有3例患者对lusutrombopag治疗均取得了良好的反应，并且能够在相同的治疗过程中进行更多的侵入性手术，而无需输注血小板。
结论：我们的初步经验支持lusutrombopag在重度肝硬化相关性血小板减少症患者中的安全性和有效性，这些患者在单疗程后接受了多个侵入性选择性手术。
